As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
The Anatolian Journal of Cardiology
Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin? [Anatol J Cardiol]
Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?
Yüksel Çavuşoğlu1Department of Cardiology and, Faculty of Medicine, Eskisehir Osmangazi University, Eskişehir-Turkey
Kronik atriyal fibrilasyonda ximelagatran warfarin’in alternatifi olamaz/Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?
Yüksel Çavuşoğlu1Department of Cardiology and, Faculty of Medicine, Eskisehir Osmangazi University, Eskişehir-Turkey
Yüksel Çavuşoğlu. Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anatol J Cardiol. 2007; 7(2): 217-219 Manuscript Language: English